ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting

This study is currently recruiting patients.

Sponsored by: Merck
Information provided by: Merck

Purpose

The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay.

Condition Treatment or Intervention Phase
Postoperative Nausea and Vomiting
 
Phase II
Phase III

MedlinePlus related topics:  Nausea and Vomiting

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, to Examine the Safety, Tolerability, and Efficacy of 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:


Location and Contact Information

Toll Free Number      1-888-577-8839 

Alabama
      Call for Information, Sheffield,  Alabama,  35660,  United States; Recruiting

California
      Call for Information, La Jolla,  California,  92093,  United States; Recruiting

      Call for Information, Pasadena,  California,  91109,  United States; Recruiting

      Call for Information, Laguna Hills,  California,  92653,  United States; Recruiting

Florida
      Call for Information, Miami,  Florida,  33136,  United States; Recruiting

Georgia
      Call for Information, Marietta,  Georgia,  30060,  United States; Recruiting

Iowa
      Call for Information, Iowa City,  Iowa,  52242-1079,  United States; Recruiting

Kansas
      Call for Information, Kansas City,  Kansas,  66160-7145,  United States; Recruiting

Kentucky
      Call for Information, Louisville,  Kentucky,  40202,  United States; Recruiting

Massachusetts
      Call for Information, Boston,  Massachusetts,  02115,  United States; Recruiting

New York
      Call for Information, Albany,  New York,  12208-3479,  United States; Recruiting

North Carolina
      Call for Information, Winston Salem,  North Carolina,  27103,  United States; Recruiting

      Call for Information, Durham,  North Carolina,  27710,  United States; Recruiting

      Call for Information, Raleigh,  North Carolina,  27609,  United States; Recruiting

Ohio
      Call for Information, Columbus,  Ohio,  43210-1240,  United States; Recruiting

Oklahoma
      Call for Information, Bartlesville,  Oklahoma,  74006,  United States; Recruiting

Pennsylvania
      Call for Information, Pittsburgh,  Pennsylvania,  15232,  United States; Recruiting

      Call for Information, Philadelphia,  Pennsylvania,  19104,  United States; Recruiting

      Call for Information, Philadelphia,  Pennsylvania,  19107-5092,  United States; Recruiting

      Call for Information, Pittsburgh,  Pennsylvania,  15261,  United States; Recruiting

      Call for Information, Pittsburgh,  Pennsylvania,  15224,  United States; Recruiting

      Call for Information, Hershey,  Pennsylvania,  17033,  United States; Recruiting

Texas
      Call for Information, Houston,  Texas,  77030-1501,  United States; Recruiting

      Call for Information, Temple,  Texas,  76508,  United States; Recruiting

      Call for Information, Houston,  Texas,  77024,  United States; Recruiting

      Call for Information, Houston,  Texas,  77030,  United States; Recruiting

Utah
      Call for Information, Murray,  Utah,  84107,  United States; Recruiting

      Call for Information, Salt Lake City,  Utah,  84124,  United States; Recruiting

      Call for Information, Salt Lake City,  Utah,  84143,  United States; Recruiting

Wisconsin
      Call for Information, Milwaukee,  Wisconsin,  53226,  United States; Recruiting

More Information

Study ID Numbers:  2004_011
Record last reviewed:  October 2004
Record first received:  August 24, 2004
ClinicalTrials.gov Identifier:  NCT00090155
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-10-29
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act